In a small prospective study on JIA‐associated uveitis, Skrabl‐Baumgartner and colleagues effectively demonstrated a link between the presence of permanent anti‐ADA antibodies, reduced ADA trough levels, loss of therapeutic response and ADA monotherapy, thus suggesting that cDMARDs should be maintained even after remission is achieved with combination therapy [21]. The gene discussed is ADA; the disease is juvenile idiopathic arthritis.